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Abstract
Background To provide recommendations for the care of
infants with stage 5 chronic kidney disease (CKD5).
Setting European Paediatric Dialysis Working Group.
Data Sources Literature on clinical studies involving infants
with CKD5 (end stage renal failure) and consensus discus-
sions within the group.
Recommendations There has been an important change in
attitudes towards offering RRT (renal replacement therapy)
to both newborns and infants as data have accumulated on
their improved survival and long-term outcomes. The man-
agement of this challenging group of patients differs in a
number of ways from that of older children. The authors
have summarised the basic recommendations for treating
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infants with CKD5 in order to support the multidisciplinary
teams who endeavour on this difficult task.
Keywords Infants . Neonates . Chronic kidney disease
(CKD) . Haemodialysis (HD) . Peritoneal dialysis (PD)
Introduction
The European Paediatric Dialysis Working Group (EPDWG)
was established in 1999 and comprises of paediatric nephrol-
ogists with a major interest in dialysis from 13 European
countries. Recommendations produced by the EPDWG
have been endorsed by the European Society of Paediatric
Nephrology.
The number of children initiating dialysis in the first year
of life has increased over the last decades. According to
international registries infants constitute 11 % of all children
initiating renal replacement therapy (RRT) [1, 2]. In Europe
the incidence of end stage renal disease (ESRD) in children
<1 year of age is between 9 and 16 per million age-related
population per year, which is nearly double the figure for the
whole paediatric age group (0–15 years) [1, 3]. In regions
where dialysis is not routinely available for neonates or
infants, the reported number of children initiating RRT in
this age group is lower. The majority of children requiring
RRT in infancy have congenital anomalies of the kidney and
urinary tract (CAKUT) or hereditary diseases [congenital
nephrotic syndrome (CNS), autosomal recessive polycystic
kidney disease (ARPKD)] which are frequently recognised
on prenatal ultrasound images. Parents need to be fully
informed at this stage on the possibilities of treatment and
survival rates for their newborn. With contemporary man-
agement, the outcome of both congenital and acquired dis-
eases (cortical necrosis, renal vein thrombosis, hemolytic
uremic syndrome) requiring RRT in infancy has greatly
improved although it is still inferior to that of older children
[4–10]. Neonates have outcomes comparable to those in
later infancy [2, 8]. An important cause of death in this
age group is due to non-renal co-morbidities. Prompt rec-
ognition of all factors which will have an impact on further
survival is a basic issue in the assessment of infants with
ESRD.
Due to the relatively small number of infant patients seen
at single centers, data from randomised trials are not avail-
able and the recommendations presented here are based on
literature research (Medline), abstracts presented at interna-
tional conferences, consensus meetings of the EPDWG and
extended e-mail discussion. The grading of the recommen-
dations is based on National Kidney Foundation Disease
Outcomes Quality Initiative (KDOQI) nomenclature and
methods [11]. Evidence level 1 indicates a recommendation
that most experts would want to be the course of action in
most patients. Evidence level 2 indicates a suggestion that
the majority of experts would want to be realised, but some
would not, and that different choices will be appropriate in
different patients, in accordance with the patients’ values
and preferences. Level A indicates high-quality scientific
evidence, B moderate, C low and D very low, implying that
the true effect will be close (A) or often far (D) from the
estimate.
Recommendation 1: Counselling for families of infants
with antenatally or postnatally diagnosed kidney disease
must involve the paediatric nephrology team
who will be providing long term care (1B).
The majority of children with stage 5 chronic kidney disease
(CKD5) in the first year of life have CAKUT (renal aplasias,
dysplasias, hypoplasias and obstructive uropathies). Among
boys, posterior urethral valve (PUV) and Prune Belly syn-
drome predominate, and in girls, the VATER (vertebral–
anal–tracheoesophageal–renal) sequence. The structural
defects can be isolated or part of a syndrome (e.g. Alagille,
Jeune syndromes). Co-morbidities are frequently present in
both isolated or syndromic CAKUT and hereditary diseases
[12, 13]. These include cardiac defects, liver and gut dis-
ease, central nervous system involvement, ear, ocular and
osseous defects. It is particularly difficult to give a firm
prognosis for antenatally detected urinary tract abnormal-
ities such as PUV as mortality often depends upon the
degree of oligohydramnios and subsequent lung function.
Prognosis should always be guarded and continuity of
support from an experienced paediatric nephrologist as
well as urologist is suggested under such circumstances.
Co-morbidities may be more frequently present in the
group with CAKUT than in infants with acquired causes
of CKD, with the former accounting for 28 % of infants in
the experience of the Italian Registry of Paediatric Chronic
Dialysis [14]. Many of these children will need a multi-
professional team approach (neonatologist, nephrologist,
urologist, gastroenterologist, cardiologist, neurologist, dieti-
tian, speech and play therapists, psychologist) and will
likely require surgical interventions during early childhood.
Enormous dedication is required from their caretakers, who
will need training and psychosocial support [15].
Contemporary management of these complex medical
problems has led to a significant improvement in the sur-
vival rates of infants with CKD5. The outcome of diseases
previously looked upon as fatal (e.g. CNS, severe ARPKD)
has significantly improved [16, 17]. Although the mortality
rate for babies starting dialysis at<1 month of age is higher
than that for older infants, the proportion who recover renal
function is greater [2]. The British Association of Paediatric
Nephrology (BAPN), North American Pediatric Renal Tri-
als and Collaborative Studies (NAPRTCS) and Italian
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Registry data confirm that neonates can initiate long-term
dialysis with outcomes comparable to those achieved in later
infancy [2, 5, 14]. A major factor influencing the final
outcome of infants with CKD5 is existing co-morbidities
[9, 10, 12, 14, 18]. Their prompt recognition and assessment
of their impact on further survival are important issues in the
decision for commencing or withholding RRT.
Recommendation 2: Consensus decision-making based
on guidelines is recommended for both commencement
and withholding of RRT in the neonate or infant (1B).
The attitudes of both primary and specialty care providers
towards the treatment of neonates and infants with ESRD
have evolved over the last decades. RRT is increasingly
looked upon as a feasible option for this age group and
initiating dialysis in infancy has become a standard practice
in developed countries. Nevertheless, nearly half of the
decisions on withholding or withdrawing life-supporting
therapy concern children<1 year of age [19]. Paediatric
nephrology centers advocate multiprofessional team discus-
sions, which may be guided by a clinical ethics committee
where appropriate, to decide upon offering RRT to newborns
and infants [20, 21]. The principle criterion used to make these
decisions is the best interest of the child. The following issues
should be addressed for discussion with members of the
medical and paramedical team:
1. Short and long-term prognosis (co-morbidities influencing
medical care and outcome).
2. Medical care issues (availability of equipment, ex-
pertise and financial resources, possibility of future
transplantation).
3. The predicted quality of life for the child (additional
disabilities) and the family. This difficult issue is associ-
ated with the feasibility of delivering high-dependency
care for the infant by the caretakers, involving their social
situation and family structure and possible sources of
support.
The parents need to obtain detailed information on all
issues and be actively involved in the decision-making
process. Withholding treatment requires careful counselling
as the outcome can be difficult to assess, especially in neo-
nates who may improve and come off dialysis. Conservative
management may last for several months, and the parents
may bond with the child and change their opinion; by this
time irreversible growth failure and developmental damage
may have occurred [22]. The decision on offering RRT to
the infant should be made as soon as possible as it will
initiate immediate intensive conservative management
aimed at attaining normal development and appropriate
planning of necessary surgical interventions prior to dialysis
or transplantation [23].
Recommendation 3: The timing of initiating RRT in infants
with CKD5 needs to be individualised with a major
determinant being maintenance of adequate growth,
nutrition and development (1B).
European guidelines recommend starting dialysis in chil-
dren when the estimated glomerular filtration rate (eGFR)
is between 15 and 10 ml/min/1.73 m2—unless the child is
growing well and is asymptomatic [24]. Infants with high
urine output may thrive despite low eGFR [25]. In infants,
eGFR is a weaker determinant for initiating dialysis.
Creatinine- and cystatin C-based estimations are less accu-
rate and often not easy to interpret. The eGFR of infants
with CKD will increase even up to 3 years of age [26].
Children with renal dysplasia who manage to achieve a
eGFR of >15 ml/min/1.73 m2 by 6 months of age will
probably not need RRT for many months or years [27].
Ultimately, 4 % of infants and 15 % of neonates may
recover renal function and terminate dialysis [1, 2]. On the
other hand, infants with CNS or ARPKD may require dial-
ysis at a relatively high eGFR due to elective nephrectomy
in preparation for transplantation in the former and nephrec-
tomy due to malignant hypertension or complications of the
nephromegaly in the latter. An important determinant of
initiating dialysis in infants is the maintenance of satisfac-
tory growth and development. Dialysis may be necessary to
achieve adequate nutrition, necessary control of metabolic
acidosis, electrolyte balance and blood pressure. Persistent
oliguria in infants will require an early start of dialysis to
prevent fluid overload due to their predominantly liquid
diet [28].
Recommendation 4: Peritoneal dialysis involves
a multidisciplinary care approach and is the preferred
modality of renal replacement therapy in infants
with CKD5 (1B).
Renal replacement therapy in infants is one of the most
challenging and demanding treatments in nephrology. An
integrated care modality should be considered and individ-
ualised for each child. Transplantation is looked upon as the
ultimate goal but will be postponed in most centres until the
infant reaches a body weight of 8–10 kg [29]. Peritoneal
dialysis (PD) is the method of choice for initiating RRT in
the youngest age group and has been shown to preserve
residual renal function which in turn improves the clearance
of larger molecules and enables provision of larger feeding
volumes. PD enables preservation of vascular access for
future use. Haemodialysis (HD) in infants and small chil-
dren is an effective and safe form of RRT and must be
available as an option, but problems with maintaining vas-
cular access limit its long-term use [30–32]. HD is chosen as
the initial mode of RRT in infants with primary oxalosis and
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those with contraindications for PD (omphalocele, gastro-
schisis, diaphragmatic hernia, obliterated peritoneal cavity,
bladder exstrophy). Short-term HD may also be necessary
following the insertion or replacement of PD catheters and
abdominal surgery.
Infant PD requires good dialysis access, as well as the
appropriate tubing and cyclers to allow low fill volumes.
Automated PD is the preferred mode of dialysis and can be
performed in infants with fill volumes greater than 100 ml
using paediatric tubing and standard cyclers with paediatric
software. The use of smaller fill volumes (< 50–60 ml) may
lead to several pitfalls:
1) Frequent alarms due to slow outflow or low flow rates
that are not detected by the cycler or negative ultra-
filtration observed in polyuric infants who reabsorb
water and sodium from the dialysate.
2) Relatively large recirculation volume (17–45 ml) may
lead to a poor clearance of uremic toxins.
For infants weighing less than 2–3 kg with fill volumes
of<100 ml short-term dialysis needs to be performed man-
ually with the use of commercially available two chamber
sets with a controlled temperature. These allow inflow and
outflow volumes to be measured with an accuracy of 1 ml.
Manual exchanges in infants are easily performed in a
hospital setting, and infants are seldom discharged home
until larger fill volumes and therefore automated PD (APD)
is achieved [33].
Recommendation 5: Surgical catheter insertion and partial
omentectomy is recommended for infants. Exit site should
be far from the diaper area and from any ostomies. Catheters
need to be immobilised to prevent tearing and pulling
and dialysis postponed for 2–3 weeks if possible allowing
healing (1C).
Paediatric-sized catheters are used for infants up to 10 kg.
Although no evidence exists on the influence of the type
of catheters used in infants on the infectious and non-
infectious complication rates, most centres use single cuff
catheters for infantsof <3 kg and double cuff catheters for
infants weighing 3–10 kg (external cuff >2 cm from exit
site).
Both straight and coiled catheters are used, although the
latter are preferred as they are shorter and catheter dislodg-
ing has been shown to be less frequent in older children
[24]. Catheters should be implanted by a dedicated surgeon
during a surgical procedure, though laparoscopic placement
has also been described in this age group. Partial omentec-
tomy is recommended due to the higher risk of catheter
obstruction in infants, but there is as yet no evidence of its
prophylactic efficacy [24, 34]. A para-median or lateral
entry into the peritoneum is performed with fixation of the
internal cuff in the rectus muscle. The exit site is lateral or
sometimes at the level of the umbilicus so as to be outside
the diaper area and at a safe distance from any ostomies on
the abdominal wall. Presternal exit sites are used in some
centres [35]. Immobilisation of the catheter by dressing is
advocated to allow healing and to prevent pulling and tear-
ing. Due to the high risk of fluid leaks and hernias in infants,
a delay of 2–3 weeks in dialysis following catheter implan-
tation is beneficial. Fibrin glue at the internal cuff has been
shown to decrease leaking complications [36]. Elective
herniotomy should be considered on the contralateral site
if there is evidence of inguinal or other hernias. Catheter
placement and the treatment of complications require the
input of a dedicated paediatric surgeon; the importance of
this specialist cannot be overestimated, as infants have a
potentially high incidence of catheter complications and
face a lifetime of renal replacement therapy [31]. Many
infants will also need careful planning of urologic proce-
dures to prepare the urinary tract for transplantation [37,
38].
Recommendation 6: The dialysis prescription in the infant
must be individualised and adapted to the infant’s urine
output and nutritional requirements (1B)
Infant dialysis will require lower fill volumes (600–900 ml/
m2), shorter dwell times (30–40 min), more frequent
exchanges (12–16) and longer duration of dialysis (10–
16 h) than older children [33, 39]. Infants tolerate lower
volumes of dialysis fluid than older children, and fill vol-
umes need to be restricted to 600–900 ml/m2. The last
(daytime) fill volume should be only one-half the night fill
volume. High fill volumes increase the risk of leakage,
hernias and gastro-oesophageal reflux and may compro-
mise respiration. Increasing the fill volume over time may
result in better ultrafiltration (UF) and clearance. Intra-
peritoneal pressure (IPP) is a helpful guide to assess the
amount of fill volume tolerated in infants and should
ideally be kept at<10 cm H2O [40]. Low fill volumes
are safer for infants but result in poor clearance and low
UF and induce a hyper-permeable exchange [41]. When
ultrafiltration is low, there is an additional risk of dialysis
recirculation in the tubing (35–45 ml). Increases in the
UF volume and a better clearance can be achieved by
shortening dwell times to 1 h or less (30–45 min),
increasing the number of exchanges to 12–16 or increas-
ing the glucose concentration in the dialysis fluid. In the
anuric infant, despite the long duration of dialysis (10–
16 h), clearance may still not be sufficient. In polyuric
infants, dialysate absorption is often seen and can be
sometimes beneficial. Additional daytime exchanges
may increase both creatinine and phosphate clearances
[42–47].
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Recommendation 7: Infants should receive biocompatible
fluids to allow for long-term preservation of the peritoneal
membrane function (1B).
There are no available studies in the infant population com-
paring the use of different dialysis fluids. It seems reason-
able to deliver the most biocompatible fluid available with
neutral pH and low levels of glucose degradation products
to minimise the adverse effects of dialysis fluids on the
infant peritoneal membrane [48, 49]. Fluids with neutral
pH preserve membrane function, and children show lower
IPP [50]. Frequent cycles can result in alkalosis and lower
buffer content dialysate is then recommended. Fluids with
the lowest possible glucose concentration should be used,
but polyuric infants may absorb fluid from low glucose
exchanges, whereas anuric children may require higher glu-
cose fluids for adequate UF [49, 51]. Calcium concentration
(1.25 or 1.75 mEq/l) needs to be individualised to provide
sufficient calcium for growth and achieve target calcium,
phosphorus and parathyroid hormone values [33, 44, 49, 52,
53]. Clinical experience with icodextrin, a colloid osmotic
agent, is limited and, consequently, it should be used with
caution in infants due to possible hyponatremia and a risk of
rebound hypoglycaemia in the daytime [54, 55]. There is no
evidence for the beneficial use of amino acid solutions in
this age group [48].
Recommendation 8: The most important measure of dialysis
adequacy is appropriate growth and development. Frequent
adjustments of the dialysis prescription and medications
are necessary to control biochemical abnormalities
and fluid status (1C).
Adequate dialysis should aim to achieve good electrolyte
and acid–base control, appropriate fluid status and accept-
able small solute clearance (residual and peritoneal). The
most sensitive measure of appropriate dialysis in infants is
appropriate growth and development [56]. Catch-up growth
was recently described in half of the infants on chronic PD,
and a positive relation was found between the length
standard deviation score (SDS) and both fill volume and
treatment duration [14]. The infant will need frequent
assessment of both growth and psychomotor development
and regular adjustments in dialysis prescriptions [57]. In the
young infant these procedures are often associated with a
prolonged period of initial hospitalisation. The successful
management of infants at home requires performance of PD
and daily measurements of weight, blood pressure, urine
output, ultrafiltration and volume of delivered nutrients
and fluids. The sum of urine output and UF needs to balance
the volume of fluids necessary to provide adequate nutrition.
The frequency of ambulatory visits is fortnightly and can
be extended in older,well-growing infants to every 3–4 weeks.
At each visit infants will require precise weight, height
and head circumference measurements (anthropometric
equipment), with documentation on a growth chart and
assessment of fluid status. These measurements provide
important information for differentiating overhydration
from weight gain. The fluid status can be assessed by
clinical judgement of the infant’s skin and mucous mem-
branes, changes in blood pressure and inappropriate
changes in weight. It is frequently difficult to differen-
tiate between fluid overload and increases in body mass.
Ultrasound vena cava inferior measurements and bioimpe-
dance are useful non-invasive methods, and atrial natri-
uretic peptide (ANP) levels may be helpful in equivocal
situations, but none are yet recommended for routine
clinical use.
Chronic hypervolaemia is common in anuric infants and
leads to hypertension and cardiac impairment. It may be
present in polyuric infants and is associated with poor
growth; it has also been reported to cause sight loss (ischae-
mic optic neuropathy). Laboratory assessments are neces-
sary at each visit for frequent adjustments of phosphate
binders and remaining medications.
The frequent exchanges, short dwell times and low fill
volume performed in infants may lead to adequate urea but
relatively poor creatinine and phosphate elimination, which
appears as a characteristic discrepancy of high kt/V (>3) and
low creatinine clearance (<50 ml/min/1.73 m2/week). The
impact of this condition is not clear but can be accepted if
the infant is biochemically stable and growth is adequate.
Sodium levels may decrease to levels present in the dialysis
fluids (132 mEq/L). Serum sodium levels correlate poorly
with sodium status. Many infants will require sodium sup-
plementation, especially those with salt-losing nephropa-
thies and/or high ultrafiltration. Sodium supplements might
be beneficial for growth.
Despite frequent exchanges and biocompatible fluids
with a normal pH, some infants still require bicarbonate
supplementation. Others demonstrate metabolic alkalosis
and will require lower buffer content dialysate.
Recommendation 9: Nutritional management is an essential
part of the management of infants on PD. Enteral feedings will
be necessary for most infants to meet the protein and caloric
requirements necessary to achieve linear growth (1B).
One of the major clinical issues of infant dialysis is adequate
nutrition for maintaining adequate growth [58]. Multi-
ple factors contribute to growth retardation in infants
with CKD, including severe anorexia, vomiting, gastro-
oesophageal reflux, fluid restriction, acidosis, salt-wasting,
renal osteodystrophy, anaemia, alteration in the gut hormon-
al balance, altered peristalsis and psychosocial deprivation.
Spontaneous intake of both nutrients and medications in the
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infant with CKD is rare, and oral supplementation and/or
enteral feedings via nasogastric tubes or gastrostomy and
supplemental feedings will be necessary for most infants to
achieve linear growth [59]. Improvement of growth should
not be taken for granted: a significant increase in weight-for-
age and body mass index (BMI)-for-age, but not of height-
for-age has been recently reported in children with CKD
after gastrostomy tube feeding, and 50 % of tube-fed sub-
jects were overweight or obese at the most recent evaluation
[60]. Although recombinant human growth hormone
(rhGH) has not been adequately investigated in infants,
recent studies suggest that early GH treatment may improve
growth [61]. A randomised controlled study has shown a
good response of infants to rhGH without adverse effects
despite concerns that infants on high caloric intake and PD
may develop insulin resistance and glucose intolerance [62].
These preliminary studies suggest that a minority of infants
who do not grow well despite good nutrition and adequate
metabolic and clinical control may benefit from GH treat-
ment with a significant improvement in body length. The
advances made in intensive nutritional treatment, which
have been achieved by the team work of nephrologists,
surgeons, gastro-enterologists, dieticians, psychologists
and dedicated cooperative parents, have dramatically im-
proved the growth and development of infants on dialysis.
Nevertheless, the psychological pressure of achieving ade-
quate growth and the additional workload of intensive nu-
trition are viewed by some parents as a greater burden than
performing PD.
An additional advantage of enteral feedings is the
possibility of delivering the numerous oral medications
prescribed, irrespective of their volume and taste and with-
out the cooperation of the infant (sodium chloride, bicar-
bonate, phosphate binders, folic acid and ferrum sulphate,
K-binding resins, antihypertensive drugs, vitamins and
antibiotics).
Nutritional support includes both supplemental feedings
and tube feedings via nasogastric tubes or gastrostomies.
Tube feedings can be delivered by syringe as a daily sup-
plementation of each natural feeding or by feeding pumps as
nightly supplementation. The basic nutrients used for tube
feeding are breast milk, infant formulas, specialised infant
formulas for CKD and high calorie or high protein supple-
ments. Nasogastric tubes may be distressing to the parents
as they are visible, require exchange every 3–6 weeks,
increase the risk of gastro-oesophageal reflux and may lead
to food aspiration. They are not recommended for infants
with existing gastro-oesophageal reflux [63–67]. The timing
of gastrostomy tube placement is very important. When the
infant’s degree of renal failure allows time for planning, a
gastrostomy tube should be placed before the need for
dialysis arises. When a child urgently requires dialysis, a
gastrostomy may be placed at the same time as a PD catheter
[24]. It is crucial to remember that gastrostomy tube place-
ment in a child established on PD carries a very high risk of
infections, including fungal peritonitis and loss of the peri-
toneal membrane [66, 67]. However, in the situation that a
child already on PD develops growth failure and requires
tube feeding, an open gastrostomy (Stamm procedure) with
adequate peri-operative antibiotic and anti-fungal cover may
be considered.
It is particularly important to place the gastrostomy tube
as soon as early signs of poor weight gain are detected as
more advanced growth failure and protein-energy wasting
will lead to poor healing post-operatively.
Nissen fundoplication may be necessary if persistent
vomiting is present despite optimisatio of anti-reflux medi-
cations. Non-infectious complications include leaks and
oesophageal herniae.
The nutrient requirements are calculated individually for
each infant, and the calorific and protein requirements differ
by centre. Calories are calculated according to the required
nutritional intake (RNI) for chronological age or height age.
Glucose absorption from the dialysate can be significant and
supply 10–20 kcal/kg/day. Most infants require RNI protein
intake, which needs to be supplemented by protein dialysate
loss and daily nitrogen losses to achieve a positive nitrogen
balance [63, 64, 68]. Albumin loss in the ultrafiltrate is
estimated to be 0.3 mg albumin/kg/day, but exact protein
losses can be easily calculated from their concentration in
total daily ultrafiltrate.
There is little information on the requirements for water-
soluble vitamins, including folic acid. It would be reason-
able to give the RNI for vitamins and micronutrients as for
normal infants. In adults on PD, blood concentrations of
some water-soluble vitamins C, B6 and folic acid are
reported to be low. In children, supplements of these vita-
mins have been given, with the result that blood concen-
trations have met or exceeded normal values [63, 69].
Recommendation 10: Centre-specific treatment is advocated
for infectious complications of infant PD according to centre
specific protocols (1B).
Mortality rates are fourfold higher in infants than in children
aged >12 years and highest for those starting dialysis at
<1 month of age [2–10, 14]. The major causes of death in
children who initiate dialysis in infancy are infections,
although dialysis-related complications as a cause of death
are relatively rare [2, 5, 57, 70]. Co-morbidities (pulmonary
disease and/or hypoplasia, severe developmental delay, con-
genital heart disease, congenital nephrotic syndrome) are
important risk factors [12–18].
The principle underlying the treatment of peritonitis
infections is preservation of the peritoneal membrane—
and not preservation of the catheter. Fungal peritonitis or
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Staphylococcus aureus peritonitis is particularly difficult
to treat and requires prompt assessment of the response
to treatment and catheter removal, if appropriate. Hae-
modialysis as a short-term “rescue’ therapy” is feasible
in infants [31, 70].
Peritonitis rates are higher in the youngest age group, and
Gram-negative organisms (“diaper peritonitis”) are more
frequent in infants [71]. In agreement with the findings of
Boehm, oligoanuria is an important risk factor for peritonitis
[72]. Gram-negative peritonitis responds poorly to empirical
treatment with ceftazidime and first generation cephalo-
sporin/glycopeptides [odds ratio (OR) 3.61, 95 % confi-
dence interval (CI) 1.73–7.54, p<0.001]. A worse response
has also been observed with intermittent dosing of ceftazi-
dime (OR 6.65, 95 % CI 2.07–21.4, p<0.005) [73, 74]. A
centre tailored empirical treatment is advocated for infants
as well as for older children with infectious complications of
PD. The intraperitoneal dosage for APD is frequently
unknown for many antibiotics, and an initial 6-hourly “con-
tinuous ambulatory peritoneal dialysis” (CAPD) dwell
regime is adopted. Systemic administration of antibiotics
may be necessary in a child who is systemically unwell or
has septicaemia. When possible antibiotic concentrations
should be measured to avoid both over- and under-dosing.
A switch to antibiotics with the lowest toxicity should be
performed once antibiotic sensitivity is known, especially if
aminoglycosides have been used for empiric therapy.
Fungal infections are more common in children with
gastrostomies, and anti-fungal prophylaxis with oral nysta-
tin and topical nystatin ointment around the gastrostomy
tube is advisable [67].
The very young patient on PD may be prone to
developing hypogammaglobulinaemia, but the latter’s
relation to the increased risk of severe infection is not
straightforward, and antibody levels to immunisations are
usually normal. There is no evidence for the routine use
of prophylactic immunoglobulins in all infants, but it is
prudent to monitor and consider replacement therapy if
low immunoglobulin levels are found in this high-risk
population for sepsis [75].
Recommendation 11: Provision of psychosocial support
and family teaching support should be an integral part
of the continuing care of infants with ESRD (1C).
The first year of life is critical for brain growth, and deficits
will have a significant impact on neurodevelopment. Early
reports described profound neurologic deficits in infants
with ESRD. More recent reports, however, show that the
developmental outcome for survivors of an infant dialysis
programme is encouraging. Improved outcomes are associ-
ated with intensive nutrition, correction of anemia and elim-
ination of aluminium as phosphate binders [76, 77]. Good
school performance has been reported in more recent eval-
uations of infant onset ESRD [7, 9]. Provision of psychoso-
cial support and family teaching support should be an
integral part of the continuing care of infants and young
children with CKD5 to compensate for frequent hospital-
isation and future poor school attendance due to chronic
illness which influences academic achievement [24].
Recommendation 12: PD is part of an integrated care
approach for infants with CKD5 in which early renal
transplantation is the ultimate goal (1B).
Although PD is feasible for both the newborn and the infant,
it is a heavy burden for the family and a great challenge for
the multispecialist team involved in their care. Renal trans-
plantation lessens the family burden of everyday dialysis
and management and improves renal function. Transplanta-
tion is associated with significant cognitive and psychomo-
tor improvement and accelerated growth [29]. The timing of
renal transplantation is dependent on both the condition and
preparation of the infant and the expertise of the transplan-
tation surgeon. Referral to a transplant center experienced in
the transplantation of infants may be warranted. The infant
on dialysis should be adequately nourished and clinically
stable, needs to complete a vaccination schedule and often
requires urologic surgery in preparation for transplantation
[16, 37, 38, 78]. Transplantation as soon as the child is
clinically and surgically stable has been advocated by some
centres [79, 80]. The current recommendation for an
adequate weight for transplantation is approximately
10 kg. Those newborns and infants that survive for trans-
plantation will have long-term outcomes similar to those of
older recipients of renal grafts and in fact have a better long-
term graft survival than teenagers [8, 10, 79–82].
Summary
Initiation of long-term dialysis in the infant as well as the
neonate is an acceptable option for both parents and
clinical staff but remains a challenge for both. Technical
advances in automated PD have lessened the burden of
dialysis. Short-term outcome has improved with intensive
nutrition and a decrease in complication rates. The long-
term outlook has also improved with increasing survival
rates for dialysis and kidney transplantation in small
children. A number of dilemmas remain, including the
management of the infant with CKD who has severe co-
morbidities and those infants deprived of family support.
Although final outcomes are still not well defined, the
available data support a more optimistic prognosis to
earlier reports for both infants and neonates embarking
on the challenge of RRT.
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